Completed PHASE3 INTERVENTIONAL NCT00021502

Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)

A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)

Sponsor: Apex Bioscience

Conditions Shock Systemic Inflammatory Response Syndrome

Interventions pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)

Updated 5 times since 2017 Last updated: Aug 13, 2009 Started: Mar 31, 2001 Primary completion: Aug 31, 2003 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Shock and Systemic Inflammatory Response Syndrome, this trial is completed. The trial is conducted by Apex Bioscience and has accumulated 5 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Apex Bioscience

Data source: Apex Bioscience

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.